Teva (TEVA) Stock Looks Cheap Even After A 378% Run

Teva Pharmaceutical Industries has delivered a powerful recovery in its share price over the past few years, which naturally puts a spotlight on what investors are really paying for today. With the stock now reflecting both that rebound and fresh product news, the live question is whether the cash the business can generate is enough to support the current valuation.

• Over the past 3 years, Teva Pharmaceutical Industries has returned about 377.9%, so a lot of future cash generation is already being treated as meaningful by the market.
• The recent FDA approval of WELTRUZA for schizophrenia may support expectations for steadier long term cash flows from Teva Pharmaceutical Industries, given the product's once monthly dosing and potential impact on patient adherence.
• Prefer to judge Teva Pharmaceutical Industries on earnings? See why Teva Pharmaceutical Industries's 67.0x P/E tells a different valuation story.

The issue now is whether Teva Pharmaceutical Industries' current share price can be explained by the cash flows implied by a Discounted Cash Flow (DCF) style intrinsic value estimate.

If you are weighing whether Teva Pharmaceutical Industries' recent 377.9% three year return and WELTRUZA launch are fairly reflected in the price, it can help to compare that cash flow story against 33 high quality undervalued stocks.

Is Teva Pharmaceutical Industries a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here projects what Teva Pharmaceutical Industries might return to shareholders through future free cash flows. Latest twelve month free cash flow sits around $1.37b, while analyst and model estimates point to higher figures over the coming decade, so the framework effectively assumes a growing cash generation profile rather than a shrinking one.

Those rising projections are being weighed against a current share price of $40.62, and on that comparison the DCF output indicates that Teva Pharmaceutical Industries' estimated intrinsic value is substantially above the current share price. FDA approval of WELTRUZA for schizophrenia helps explain why the cash flow outlook in the model is constructive, yet the price still trails what this discounted cash flow approach suggests the business could be worth over time. Find out what Teva Pharmaceutical Industries could be worth using our Discounted Cash Flow (DCF) estimate.

The Teva Pharmaceutical Industries Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Teva Pharmaceutical Industries' valuation puzzle leaves off. Narratives spell out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page as ongoing reference points. Each one frames Teva Pharmaceutical Industries' fair value as a thesis that can be tracked over time, rather than a one off snapshot.

A clear, numbers-based narrative on Teva Pharmaceutical Industries gives you a fixed reference point that can be updated as actual free cash flow, leverage and returns either support or challenge the current DCF assumptions. With the WELTRUZA launch approved and moving toward commercialization, a written view also helps you track whether that product actually changes Teva Pharmaceutical Industries' long-run cash generation in a way that aligns with or diverges from today's pricing.

Share your own Narrative for Teva Pharmaceutical Industries and set out the assumptions behind your valuation.

Teva Pharmaceutical Industries: Why the story is not just about price

Teva Pharmaceutical Industries may look straightforward on valuation, yet internal checks have surfaced caution flags that deserve attention alongside any cash flow work you do. Take a closer look at 2 warning signs (1 major) before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com